Large-scale computational analysis of patient data leads to better models of disease progression. (Read more)
A series of recent papers showcases an emerging approach to data analysis in which open ‘challenges’ are issued to the research community to solicit computational methods that can solve important scientific questions. (Read more)
Community with Big DREAMs ….. One of the most remarkable developments in biomedicine over the last decade is the dramatic increase in speed and reduction in cost (Read more)
NCI DREAM paper on Drug Sensitivity prediction was chosen as in the Top 10 papers in 2014 by the ISCB. Read More.
Over the last several years, we’ve run DREAM Challenges under diverse funding models that were based on the either the generosity of scientists donating their time or funding from grants or both. This year we are expanding our funding model through crowd-funding, to raise funds to support monetary prizes for a second DREAM Challenge focused on ALS. The idea is to motivate hundreds of researchers to leverage new clinical data to help find new treatments for ALS by better understanding the disease. The Prize4Life’s crowdfunding site is available on Indiegogo during this sneak preview “Soft Launch” phase. Read More
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive and ultimately fatal neurodegenerative disease affecting 1 in 400 people in which the motor neurons die. There is only one approved treatment but no shortage of clinical trials. Read More.
Using data from old clinical trials, two groups of researchers have found a better way to predict how amyotrophic lateral sclerosis (ALS) progresses in different patients. Read more
A joint blog post discussing Google Cloud’s involvement in the DREAM Somatic Mutation Calling Challenge. Read more
Andrew Lash at Xconomy discusses a variety of efforts to better understand Alzheimer’s Disease, including the DREAM AD#1 Challenge. Read more
A study published June 1 in the journal Nature Biotechnology describes the results of an open challenge to predict which breast cancer cell lines will respond to which drugs, based only on the sum of cells’ genomic data. Read more